# OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial

> **NCT06558214** · PHASE2 · RECRUITING · sponsor: **University of Florida** · enrollment: 20 (estimated)

## Conditions studied

- Recurrent Glioblastoma

## Interventions

- **DRUG:** Pembrolizumab
- **DEVICE:** Optune GIO®
- **DEVICE:** NeuroBlate®

## Key facts

- **NCT ID:** NCT06558214
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-10
- **Primary completion:** 2029-10
- **Final completion:** 2029-10
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06558214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06558214, "OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06558214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*